A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations

Journal of Gastrointestinal Surgery

Volumn 15, Issue 2, 2011, Pages 267-276

  Ananthakrishnan, Ashwin N ^a,c   McGinley, Emily L ^a   Binion, David G ^b   Saeian, Kia ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Crohn's disease; Hospitalization, surgery, colectomy; IBD; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

ADULT; AGED; ARTICLE; COLON RESECTION; CROHN DISEASE; ELECTIVE SURGERY; FACTUAL DATABASE; FEMALE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; STATISTICAL MODEL; STATISTICS; ULCERATIVE COLITIS; UNITED STATES;

ADULT; AGED; COLECTOMY; COLITIS, ULCERATIVE; CROHN DISEASE; DATABASES, FACTUAL; FEMALE; HOSPITALIZATION; HUMANS; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; SURGICAL PROCEDURES, ELECTIVE; UNITED STATES;

EID: 79751531102     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-010-1396-3     Document Type: Article

References (32)

1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. Gastroenterology. Dec 2008; 135(6): 1907-1913.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. May 4 2002; 359(9317): 1541-1549.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. Feb 26 2004; 350(9): 876-885.
4. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. Oct 9 1997; 337(15): 1029-1035.
5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. Jan 2007; 132(1): 52-65.
6. Feagan BG, Panaccione R, Sandborn WJ, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. Nov 2008; 135(5): 1493-1499.
7. Sandborn WJ, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. Jun 19 2007; 146(12): 829-838.
8. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. Jul 19 2007; 357(3): 239-250.
9. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. Nov 3 2005; 353(18): 1912-1925.
10. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. Dec 8 2005; 353(23): 2462-2476.
11. Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A novel risk score to stratify severity of Crohn's disease hospitalizations. Am J Gastroenterol. 2010;(in press).
12. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. Feb 2005; 54(2): 237-241.
13. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. May 2007; 5(5): 597-601.
14. Cannom RR, Kaiser AM, Ault GT, Beart RW, Jr., Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am Surg. Oct 2009; 75(10): 976-980.
15. Nguyen GC, Tuskey A, Dassopoulos T, Harris ML, Brant SR. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. Dec 2007; 13(12): 1529-1535.
16. Odes S. How expensive is inflammatory bowel disease? A critical analysis. World J Gastroenterol. Nov 21 2008; 14(43): 6641-6647.
17. HCUP Nationwide Inpatient Sample (NIS). Healthcare Cost and Utilization Project (HCUP). 2004. Agency for Healthcare Research and Quality, Rockville, MD. Available at: www. hcup-us. ahrq. gov/nisoverview. jsp. Accessed 23 December 2007.
18. Whalen D, Houchens R, Elixhauser A. 2004 HCUP Nationwide Inpatient Sample (NIS) Comparison Report. HCUP Methods Series Report # 2007-03 Online February 2, 2007. U. S. Agency for Healthcare Research and Quality. Available at: http://www. hcup-us. ahrq. gov/reports/methods. jsp.
19. Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am J Gastroenterol. Nov 2008; 103(11): 2789-2798.
20. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. Jan 1998; 36(1): 8-27.
21. Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A simple risk score to identify colectomy risk in Ulcerative Colitis hospitalizations. Inflamm Bowel Dis. 2009;(in press).
22. Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. Jan 2006; 101(1): 110-118.
23. Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can J Gastroenterol. Aug 2007; 21(8): 507-511.
24. Jess T, Riis L, Vind I, et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis. Apr 2007; 13(4): 481-489.
25. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. Apr 2005; 128(4): 862-869.
26. Rubenstein JH, Chong RY, Cohen RD. Infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. Aug 2002; 35(2): 151-156.
27. Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn's disease. Am J Gastroenterol. Nov 2009; 104(11): 2754-2759.
28. Punati J, Markowitz J, Lerer T, et al. Effect of early immunomodulator use in moderate to severe pediatric Crohn disease. Inflamm Bowel Dis. Jul 2008; 14(7): 949-954.
29. Bojic D, Radojicic Z, Nedeljkovic-Protic M, Al-Ali M, Jewell DP, Travis SP. Long-term outcome after admission for acute severe ulcerative colitis in Oxford: the 1992-1993 cohort. Inflamm Bowel Dis. Jun 2009; 15(6): 823-828.
30. Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute severe ulcerative colitis in the infliximab era. Dig Liver Dis. Oct 2008; 40(10): 821-826.
31. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. Jun 2005; 128(7): 1805-1811.
32. Regueiro M, Curtis J, Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol. Jul 2006; 40(6): 476-481.